Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emmessar Biotech And NutritionBOM:524768 +0.98%57 PS Ratio is 34.66 as of Aug. 09, 2026, which is 152% above its 10-year median of 13.77. GuruFocus rates BOM:524768 with a GF Score™ of 57/100 and a GF Value™ of ₹18.60 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 953 Drug Manufacturers companies, Emmessar Biotech And Nutrition ranks worse than 96.01% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Emmessar Biotech And Nutrition's share price is ₹25.65.
Emmessar Biotech And Nutrition's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.74. Hence, Emmessar Biotech And Nutrition's PS Ratio for today is 34.66.
The historical rank and industry rank for Emmessar Biotech And Nutrition's PS Ratio or its related term are showing as below:
BOM:524768'
s PS Ratio Range Over the Past 10 Years
Min: 1.1 Med: 13.77 Max: 53.06
Current: 34.66
During the past 13 years, Emmessar Biotech And Nutrition's highest PS Ratio was 53.06. The lowest was 1.10. And the median was 13.77.
BOM:524768's PS Ratio is ranked worse than 96.01% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs BOM:524768: 34.66
Emmessar Biotech And Nutrition Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Emmessar Biotech And Nutrition was -37.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -28.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -32.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -15.20% per year.
During the past 13 years, Emmessar Biotech And Nutrition's highest 3-Year average Revenue per Share Growth Rate was 77.40% per year. The lowest was -57.00% per year. And the median was -16.65% per year.
Emmessar Biotech And Nutrition (BOM:524768) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Emmessar Biotech And Nutrition PS Ratio Related Terms
Emmessar Biotech And Nutrition PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Emmessar Biotech And Nutrition's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmessar Biotech And Nutrition PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emmessar Biotech And Nutrition's PS Ratio distribution charts can be found below:
* The bar in red indicates where Emmessar Biotech And Nutrition's PS Ratio falls into.
Emmessar Biotech And Nutrition PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Emmessar Biotech And Nutrition's Share Price of today is ₹25.65. Emmessar Biotech And Nutrition's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.74.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Emmessar Biotech And Nutrition (BOM:524768) has a PS Ratio of 34.66 as of Aug. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Emmessar Biotech And Nutrition and its competitors. This is 152% above median its historical median of 13.77. Over the past decade, Emmessar Biotech And Nutrition's PS Ratio has ranged from 1.10 to 53.06. According to the industry distribution chart, Emmessar Biotech And Nutrition ranks #915 out of 953 companies in the Drug Manufacturers industry, placing it in the top 96%.
Is Emmessar Biotech And Nutrition's PS Ratio too high?
Emmessar Biotech And Nutrition's current PS Ratio of 34.66 is 152% above median its 10-year median of 13.77. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 53.06. The Drug Manufacturers industry median PS Ratio is 2.35. Emmessar Biotech And Nutrition's value of 34.66 is 1374.9% above this industry median. Based on the distribution chart, Emmessar Biotech And Nutrition ranks #915 out of 953 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Emmessar Biotech And Nutrition has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emmessar Biotech And Nutrition's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emmessar Biotech And Nutrition ranks #915 out of 953 companies for PS Ratio. This places Emmessar Biotech And Nutrition in the lower half of its industry. The industry median PS Ratio is 2.35. Emmessar Biotech And Nutrition's value of 34.66 is 1374.9% above this benchmark. Historically, Emmessar Biotech And Nutrition's own PS Ratio has ranged from 1.10 to 53.06 over the past decade. While the company's 10-year median is 13.77 vs. the industry median of 2.35, Emmessar Biotech And Nutrition has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmessar Biotech And Nutrition's current PS Ratio of 34.66 is 1374.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Emmessar Biotech And Nutrition and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmessar Biotech And Nutrition's current PS Ratio is 34.66, which is 152% above median its own 10-year median of 13.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmessar Biotech And Nutrition stock overvalued right now?
Based on GuruFocus' analysis, Emmessar Biotech And Nutrition (BOM:524768) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹18.60, compared to a current price of ₹25.65 — trading 37.9% above its estimated fair value. The current PS Ratio is 34.66, which is 152% above median its 10-year median of 13.77 and 1374.9% above the Drug Manufacturers industry median of 2.35. Emmessar Biotech And Nutrition's overall GF Score™ is 57/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Emmessar Biotech And Nutrition (BOM:524768), the current PS Ratio is 34.66 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emmessar Biotech And Nutrition (BOM:524768) Overvalued in 2026?
Based on GuruFocus' analysis, Emmessar Biotech And Nutrition stock appears to be overvalued.
The current stock price of ₹25.65 is trading 37.9% above its estimated GF Value™ of ₹18.60.
GuruFocus considers Emmessar Biotech And Nutrition to be Significantly Overvalued.
Key valuation signals for BOM:524768:
PS Ratio: 34.66 (152% above median its 10-year median of 13.77)
GF Value™: ₹18.60 vs. price of ₹25.65 (37.9% above fair value)
Industry Position: 1374.9% above the Drug Manufacturers median (#915 of 953)
No single metric tells the full story. See the BOM:524768 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emmessar Biotech And Nutrition Ltd is a healthcare company. The company is engaged in the manufacturing and marketing of fine chemicals products, and healthcare and nutritional products. The company caters to patients with obstinate skin problems, muscle problems, bone problems, and other debilitating chronic physical ailments. The business segments of the company are Healthcare, Fine Chemicals, and Rent on Immovable property of which the majority of the revenue is derived from the Rent on Lease land segment.
57GF Score
Get the complete analysis for BOM:524768
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524768 has been successfully added to your 
